

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Investigating psychobiological causes and mechanisms in functional seizures and functional motor symptoms: Study protocol

Susannah Pick^{1*}, Anthony S. David², Mark J. Edwards¹, Laura H. Goldstein¹, John Hodsoll¹, L. S. Merritt Millman¹, Timothy R. Nicholson¹, A.A.T.S. Reinders¹, Biba Stanton^{1,3}, Joel S. Winston^{1,3}, Mitul A. Mehta¹, Trudie Chalder¹, Matthew Hotopf^{1,4}

¹Institute of Psychiatry, Psychology & Neuroscience, King’s College London
²Institute of Mental Health, University College London
³King’s College Hospital NHS Foundation Trust
⁴South London & Maudsley NHS Foundation Trust

Corresponding author: Dr Susannah Pick*

Address: Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, 16 De Crespigny Park, London, SE5 8AF
Email: susannah.pick@kcl.ac.uk

Word count: 5200

25 **Abstract**

26

27 **Introduction:** Advances have been made in understanding the aetiology of functional
28 neurological disorder (FND); however, its pathophysiological mechanisms have not been
29 definitively demonstrated. Evidence suggests interacting roles for altered emotional
30 processing and interoception, elevated autonomic arousal, and dissociation, but there is
31 limited evidence demonstrating their causal influence on specific FND symptoms. Our
32 superordinate aim is to elucidate potentially shared and distinct aetiological factors and
33 mechanisms in two common FND subtypes, functional seizures (FS) and functional motor
34 symptoms (FMS).

35 **Methods:** This study has a multimodal, mixed between- and within-groups design. The target
36 sample is 50 individuals with FS, 50 with FMS, 50 clinical controls (anxiety/depression), and
37 50 healthy controls. Potential aetiological factors (e.g., adverse life events, physical/mental
38 health symptoms, dissociative tendencies, interoceptive insight/sensibility) will be assessed
39 with a detailed medical history interview and self-report questionnaires. A laboratory session
40 will include a neurocognitive battery, psychophysiological testing, cardiac interoception and
41 time estimation tasks and an isometric handgrip task. A subsample will undergo magnetic
42 resonance imaging, including structural, resting-state and task-based scans combined with
43 psychophysiological recording. Remote monitoring with ecological momentary assessment
44 and wearables will measure variability in FND symptoms and in patients' daily lives and
45 their potential predictors/correlates for ≥ 2 weeks. Longitudinal follow-ups at 3, 6, and 12-
46 months will monitor longer-term outcomes in the clinical groups.

47 **Discussion:** This study employs multimodal research methods to rigorously examine several
48 putative mechanisms in FND, at subjective/experiential, behavioural, and physiological
49 levels. The study will test causal hypotheses about the role of altered emotional processing,
50 autonomic arousal, dissociation and interoception in the initiation or exacerbation of FND
51 symptoms, directly comparing these processes in FS and FMS to healthy and clinical
52 controls. This is the first study of its kind, with potential to reveal important targets for
53 prevention and treatment of FND in future.

54

55

56

57 **Key Words:** non*epileptic seizures; conversion disorder; dissociative seizures; functional
58 movement disorder; digital; MRI.

59

60 **Introduction**

61 Functional neurological disorder (FND) is a complex neuropsychiatric disorder defined by
62 the presence of neurological symptoms (motor, sensory, seizure) that are not caused by or
63 compatible with identifiable neuropathology (APA, 2013; WHO, 2019). FND is commonly
64 associated with impaired quality of life, diminished functioning, psychological distress and
65 significant healthcare costs (Carson & Lehn, 2016). Individuals with FND experience
66 considerable stigma and barriers to accessing appropriate treatment, which is exacerbated by
67 uncertainty regarding causation and mechanisms.

68 It is now accepted that there is a wide range of psychological, social and biological
69 aetiological factors associated with FND, including stressful life events, mental health
70 symptoms/disorders, relationship problems and significant physical injuries and illnesses
71 (Brown & Reuber, 2016; Morsy et al., 2021; Reuber, 2009). However, precisely how these
72 factors contribute to FND is still not fully understood and there is a need for more rigorous
73 research into the mechanisms underlying FND symptoms.

74 Recent perspectives have highlighted the potential role of altered emotional
75 information processing and elevated autonomic arousal in FND (Brown & Reuber, 2016;
76 Drane et al., 2020; Pick et al., 2019). Previous experimental evidence has shown that people
77 with FND exhibit differences in autonomic and/or subjective responses to affective stimuli
78 (e.g., Pick, Mellers & Goldstein, 2018a; Pick et al., 2023; Roberts et al., 2012), reduced
79 recognition and attentional biases to emotional facial expressions (Bakvis et al., 2009; Pick,
80 Mellers & Goldstein, 2016; 2018b), altered bodily awareness (interoception) (Koreki et al.,
81 2020; Pick et al., 2020; Williams et al. 2021), and divergent patterns of neural activation
82 during exposure to affective stimuli (e.g., Aybek et al., 2015; Espay et al., 2018). There is
83 also accumulating evidence to support the view that dissociation may be an important

84 underlying pathophysiological process (e.g., Campbell et al., 2022; Koreki et al., 2020; Pick,
85 Mellers & Goldstein, 2017; Pick et al., 2020).

86 Despite advances in the understanding of FND, there remain some important
87 unanswered questions. Firstly, few studies have examined explicitly the potential temporal
88 relationships between key pathophysiological processes (e.g., autonomic arousal, limbic
89 hyperactivation) and the occurrence of FND symptoms (Pick et al., 2019). Evidence for
90 causal relationships between putative mechanistic processes and FND symptoms is therefore
91 limited, with many previous studies demonstrating only correlational relationships. There is a
92 paucity of studies directly comparing potential causal factors and pathophysiological
93 mechanisms in different FND subtypes, and the possible links between background
94 aetiological factors and mechanistic processes in these subgroups require further
95 examination. Furthermore, there is little evidence linking specific aetiological factors and
96 mechanistic processes to longer-term outcomes in FND.

97

98 *Aims & objectives*

99 The overall aim of this project is to elucidate the shared and distinct psychobiological causes
100 and mechanisms of functional seizures (FS) and functional motor symptoms (FMS), using a
101 novel combination of multi-modal research methods.

102 The primary objective is to examine the hypothesised influence of autonomic arousal
103 and limbic system hyperactivation on subjective FS and FMS symptoms (Pick et al., 2019).

104 Secondary objectives are as follows:

- 105 • Assess a range of biological, psychological and social aetiological factors in people
106 with FS and FMS, including adverse life events, psychological distress and
107 dissociative tendencies.
- 108 • Examine relationships between background factors (e.g., adverse experiences),
109 psychobiological mechanisms (e.g., autonomic arousal, limbic hyperactivity, bodily
110 awareness) and clinical outcomes (i.e., symptom severity, functioning, quality of life).
- 111 • Identify the similarities and differences in background factors and pathophysiological
112 processes in the FND groups (FS, FMS) relative to individuals with elevated
113 psychological symptoms (anxiety, depression), who do not experience neurological
114 symptoms.
- 115 • Examine factors that might trigger the occurrence or worsening of FS and FMS
116 symptoms in patients' daily lives in real-world contexts, including the possible
117 influence of autonomic arousal, sleep disturbance, physical exertion, daily events and
118 mood variations.

119 To achieve these objectives, the following methods are being employed:

- 120 • An in-depth interview and self-report questionnaires to capture data on a range of
121 possible predisposing, precipitating and perpetuating factors.
- 122 • Standardised neurocognitive tests to examine core cognitive domains implicated in
123 the pathophysiology of FND, including attention (Edwards et al., 2012), executive
124 functions (Brown & Reuber, 2016), and social cognition (Pick et al., 2019).
- 125 • Experimental and psychophysiological measures to probe behavioural, cognitive and
126 physiological responses to bodily sensations and affectively significant stimuli.
- 127 • Neuroimaging to assess structural and functional brain differences in people with FS
128 and FMS, compared to both healthy and clinical controls.

- 129 • Remote monitoring with smartphone applications and a wearable device to collect
130 data on the possible antecedents of FS and FMS in ‘real-time’ and ‘real-world’
131 contexts.
- 132 • Remote follow-up sessions at 3, 6, and 12-months to examine longer-term clinical
133 outcomes.

134

135 The primary hypotheses being tested are:

- 136 1. Individuals with FS and FMS will exhibit elevated autonomic activation (heart rate,
137 electrodermal activity) in response to affectively significant stimuli and events,
138 compared to healthy and clinical controls.
- 139 2. Elevated autonomic arousal and associated hyperactivation in limbic brain regions
140 will temporally precede the occurrence or exacerbation of FS and FMS.

141

142 The secondary hypotheses include the following:

- 143 1. People with FS and FMS will display alterations in bodily awareness (interoception)
144 and associated neural activity, compared to controls.
- 145 2. Participants with FS and FMS will exhibit differences in executive functioning (e.g.,
146 attentional allocation, response inhibition) and social cognition compared to controls,
147 despite intact general cognitive functioning.
- 148 3. FS and FMS symptom severity will be exacerbated in daily life by emotionally salient
149 events, dissociation, and negative affect.
- 150 4. Worse clinical outcomes (symptom severity, quality of life, functioning,
151 psychological distress) will be predicted by adverse life event burden, elevated
152 autonomic arousal, limbic hyperactivation, and greater psychological dissociation.

153 **Materials and methods**

154 This study underwent peer-review by four independent reviewers during funding acquisition
155 (Medical Research Council UK) and has been reviewed/approved by the Health Research
156 Authority and an NHS Research Ethics Committee (‘Ethical considerations’). This is a single
157 centre study; all research activities are taking place at, or being coordinated from, the
158 Institute of Psychiatry, Psychology and Neuroscience, King’s College London.

159

160 ***Study Design***

161 This project has a mixed between- and within-groups design, including observational,
162 experimental, cross-sectional and longitudinal measures. The FS and FMS samples are being
163 compared to healthy and clinical control groups.

164

165 ***Primary endpoints***

- 166 • FS and FMS occurrence and severity, measured with repeated momentary
167 assessments during the laboratory, neuroimaging and remote monitoring procedures.
- 168 • Autonomic arousal, measured with heartrate and/or electrodermal activity levels
169 during the laboratory, neuroimaging and remote monitoring procedures.
- 170 • Limbic and paralimbic system hyperactivation, measured with region-of-interest
171 neuroimaging analyses.

172 ***Secondary endpoints***

- 173 • FS and FMS severity, occurrence, and impact, measured with self-report
174 questionnaires at baseline and 3, 6 and 12-month follow-up.

- 175 • Psychological dissociation, measured with momentary assessments during the
176 laboratory, neuroimaging session and remote monitoring phased, and with validated
177 scales at baseline and follow-up.
- 178 • Interoceptive accuracy and awareness, and associated functional brain activity (i.e.,
179 insula), measured with experimental tasks and self-report measures at baseline, during
180 the laboratory session and at follow-up, and with region-of-interest analyses in the
181 neuroimaging study.
- 182 • Cognitive functioning, measured with standardised neurocognitive tests and
183 experimental tasks during the laboratory session.
- 184 • Work, social and physical functioning, measured with validated scales at baseline and
185 at follow-up.
- 186 • Health-related quality of life, also measured with a validated questionnaire at baseline
187 and follow-up.

188

189 ***Pilot study***

190 The design of this project has been informed by a pilot study which was conducted between
191 July-October 2022, including 17 participants with FMS and/or FS and 17 healthy controls.

192 The pilot study included all procedures proposed here, except the neuroimaging session. The
193 aim was to test the acceptability and feasibility of the procedures, and to ensure that the tasks
194 planned for the neuroimaging session were well-tolerated and valid. The 34 participants who
195 entered the study completed all elements of the research. Feedback was elicited from
196 participants, which has now been incorporated into this protocol. The findings of the pilot
197 study have been reported elsewhere (Millman et al., 2023, 2024; Pick et al., 2023a,b).

198

199 ***Patient/public involvement***

200 An FND Patient and Carer Advisory Panel (FND-PCAP) was convened in 2022 to consult
201 with the team throughout the project on the design, implementation and dissemination of the
202 project. The FND-PCAP includes patients with FND, carers, and representatives of patient
203 support organisations (FND Hope UK, FND Action).

204

205 ***Participants***

206 Fifty participants diagnosed with FS and 50 with FMS will be recruited in total, in addition to
207 50 healthy control participants and 50 matched clinical control participants. The groups will
208 be frequency-matched for age, sex/gender, and handedness. The eligibility criteria are
209 detailed below.

210

211 ***Inclusion criteria***

212 All participants:

- 213
- 214 • 18-65 years old
 - 215 • Normal or corrected eyesight
 - 216 • Fluency in English language

217 Participants with FS:

- 218 • A primary diagnosis of functional seizures made by a Consultant
Neurologist/Epileptologist, in the absence of functional motor symptoms
- 219 • Currently meets DSM-5 criteria for FND
- 220 • Minimum seizure frequency of 2 per month, with premonitory symptoms

221 Participants with FMS:

222 • A primary diagnosis of functional motor symptoms made by a Consultant
223 Neurologist, in the absence of functional seizures

224 • Currently meets DSM-5 criteria for FND

225 Clinical control participants:

226 • Presence of anxiety disorder or major depression, confirmed with DSM-5 criteria
227 during the screening interview (Quick SCID)

228 *Exclusion criteria*

229 All participants:

230 • Diagnosis of major comorbid cardiovascular (e.g., heart disease), active severe
231 psychiatric disturbance (e.g., psychosis, alcohol, or substance dependence) or
232 neurological disorder (e.g., epilepsy, multiple sclerosis) that would either confound
233 the findings or impair the participant's ability to participate

234 • Physical symptoms / disability impairing ability to perform tasks (e.g.,
235 severe/constant tremor, bilateral upper limb paralysis, daily seizures)

236 • Current participation in another interventional study (e.g., treatment trial,
237 experimental study)

238 Neuroimaging study:

239 • Ineligibility to undergo MRI imaging, for example the presence of a cardiac
240 pacemaker or other electronic device or ferromagnetic metal foreign bodies.

241 • Participant weight in excess of 126kg or physical dimensions such that the
242 participant may not fit in the MRI scanner.

243 • A history of claustrophobia or participant reports symptoms triggered in confined
244 spaces or participant feels unable to lie in an MRI scanner for a period of up to 90
245 minutes.

269 research cohorts (e.g., the Genetic Links to Anxiety and Depression study

270 [<https://gladstudy.org.uk/>]).

271 Potential participants who express interest in the study and appear to be eligible at initial
272 screening are provided with a Participant Information Sheet (PIS) and Informed Consent Form
273 (ICF) by their clinician or the research team.

274 (insert Figure 1 near here)

275

276 *Informed Consent Procedures*

277 There are three written informed consent procedures during this study, as follows:

- 278 1. Main consent form: Participants who appear to be eligible at initial contact are asked to
279 complete a consent form electronically for completion of the screening interview,
280 background questionnaires, and laboratory session. Consent for this stage is obtained
281 at least 48 hours after participants received the PIS/ICF, unless a participant decides to
282 participate sooner, in which case they are able to contact the research team directly.
- 283 2. Neuroimaging: Another ICF is completed for the MRI session, either electronically or
284 in person. If seemingly eligible at initial screening, participants are given a separate
285 neuroimaging PIS and ICF for consideration for at least 48 hours.
- 286 3. Remote monitoring: Participants complete another ICF, electronically or in person, for
287 participation in the remote monitoring phase, prior to installing the smartphone
288 applications on their mobile devices.

289 Consent is obtained at all timepoints by a member of the immediate research team, only after
290 participants' questions have been answered and a full, detailed explanation of the research
291 activities has been provided.

292

293 *Screening Procedures*

294 All participants are screened initially for eligibility by either a member of the research team or
295 a local clinician. Potential participants are assessed for eligibility briefly on the basis of current
296 physical or mental health diagnoses, FND symptoms (if applicable), and medications. Those
297 candidates appearing to meet the eligibility criteria are asked to provide informed consent prior
298 to participating in a detailed screening interview with a senior member of the research team by
299 telephone or online. During the interview, participants complete a detailed background
300 sociodemographic and medical history questionnaire, followed by a brief structured clinical
301 interview (Quick SCID; First & Williams, 2021). Eligibility for all elements of the study,
302 including neuroimaging, are evaluated at this stage. Following the interview, participants are
303 informed of the outcome. Should the candidate not be eligible to progress into the main study,
304 they are given a detailed explanation and reimbursed for their time with a £10 shopping
305 voucher.

306

307 ***Schedule of Assessments***

308 *Online self-report questionnaires*

309 Eligible participants are emailed a weblink to a set of self-report questionnaires (Qualtrics),
310 which assess the following aetiological factors:

- 311 • Life events (Traumatic Experiences Checklist; Nijenhuis, Van der Hart, & Kruger,
312 2002)
- 313 • Trauma-related distress (Posttraumatic Stress Diagnostic Scale – Self-Report Version
314 for DSM-5; Foa et al., 2016)
- 315 • Work and social functioning (Work and Social Adjustment Scale; Mundt, Marks,
316 Shear, & Greist, 2002)

- 317 • Health-related quality of life (Short Form Health Survey – 36 item; Hays, Sherbourne,
318 & Mazel, 1993)
- 319 • Psychological distress (Patient Health Questionnaire-9; Kroenke, Spitzer, & Williams,
320 2001 / Generalized Anxiety Disorder-7; Spitzer, Kroenke, Williams, & Lowe, 2006)
- 321 • Physical symptom burden (Patient Health Questionnaire-15; Kroenke, Spitzer, &
322 Williams, 2002)
- 323 • Interoceptive abilities (Interoceptive Accuracy Scale, Murphy et al., 2020;
324 Interoceptive Attention Scale, Gabriele et al., 2022; Multidimensional Assessment of
325 Interoceptive Awareness-2, Mehling et al., 2018)
- 326 • Dissociative tendencies (Somatoform Dissociation Questionnaire-20; Nijenhuis,
327 Spinhoven, Van Dyck, Van der Hart, & Vanderlinden, 1996; Multiscale Dissociation
328 Inventory; Briere, 2005)
- 329 • Alexithymia (Toronto Alexithymia Scale-20; Bagby, Taylor, & Parker, 1994)
- 330 • Autistic traits (Autism Spectrum Quotient; Baron-Cohen, Wheelwright, Skinner,
331 Martin, & Clubley, 2001)
- 332 • FND symptoms (bespoke questionnaire assessing the presence and severity of FND
333 symptoms)
- 334 • Illness-related cognitions (Brief Illness Perceptions Questionnaire; Broadbent, Petrie,
335 Main, & Weinman, 2006 / Cognitive Behavioural Responses Questionnaire; Ryan,
336 Vitoratou, Goldsmith, & Chalder, 2018)
- 337 • Subjective cognitive symptoms (Cognitive Failure Questionnaire; Broadbent, Cooper,
338 FitzGerald, & Parkes, 1982)

339

340 *Laboratory session*

341 Participants are next invited to attend a laboratory session, consisting of two parts separated by
342 a break of approximately 30-60 minutes.

343

344 Part 1: Standardised neurocognitive testing

345 1. Wechsler Abbreviated Scale of Intelligence (second edition, WASI-II, Wechsler, 2011)
346 assesses general cognitive abilities.

347 2. A CANTAB Connect cognitive test battery

348 (<https://www.cambridgecognition.com/products/cognitive-research/>) measures

349 executive functions, attention, psychomotor response speed, and social cognition.

350 3. A performance validity test assesses engagement and motivation (Green et al., 2003).

351 4. Performance evaluations: Participants rate their performance on each test using a 7-
352 point Likert-scale.

353 Part 2: Experimental cognitive tasks and psychophysiology

354 After the break, participants complete brief computerised tasks and psychophysiological

355 testing administered with E-Prime experimental software ([https://pstnet.com/products/e-](https://pstnet.com/products/e-prime/)

356 [prime/](https://pstnet.com/products/e-prime/)) and a Powerlab psychophysiological data acquisition system

357 (<https://www.adinstruments.com/products/powerlab-daq-hardware>). The measures are as

358 follows:

359 1. Psychophysiology: Electrodermal activity (skin conductance) and heartrate
360 (electrocardiography) monitor autonomic activation.

361 2. Heartbeat tracking and time estimation tasks measure cardiac interoception and
362 time perception respectively.

363 3. Computerised subjective probes assess momentary psychological and physical
364 states (Table S1).

365 4. Grip contraction task: Participants repeatedly grip a dynamometer device with their
366 dominant hand at maximum effort for short periods, separated by rests.

367 Participants are compensated with a £50 shopping voucher on completion of the
368 laboratory session.

369 *Neuroimaging*

370 Participants eligible for MRI scanning return to complete the session on a separate day. The
371 session lasts a maximum of 90-minutes, including the following components:

- 372 1. Structural scans (~10 mins).
- 373 2. Resting-state functional scan (~10 mins).
- 374 3. Interoceptive attention task: Participants direct their attention to their heartbeat
375 sensations or an exteroceptive stimulus (~10 mins).
- 376 4. Affective images task: Participants view blocks of positive, negative and neutral
377 images (International Affective Picture System; Lang et al., 2008). After each
378 block, participants report on momentary physical and psychological states (Table
379 S2). Heartrate and electrodermal activity are monitored throughout (~25-30 mins).
- 380 5. Interoceptive attention task repeated.

381 Participants are compensated with a £50 shopping voucher on completion of the
382 session.

383

384 *Remote monitoring phase (2-4 weeks duration)*

385 The initial remote monitoring phase includes collection of data on participants' behaviours,
386 experiences and physiological signals for two weeks in their everyday lives.

387 Participants receive support and training from the research team on installation and use
388 of the smartphone applications (Real Life Exp / Fitbit). The ecological momentary assessment

389 (EMA) protocol involves brief electronic questions daily (6 times per day) on physical and
390 psychological states, and daily events (Table S1). Each data collection point is triggered by a
391 notification from the RealLife Exp application and takes 1-2 minutes to complete. The
392 notifications are sent at pseudorandom intervals during waking hours (9am-9pm). The
393 notifications do not arrive less than one-hour apart. Participants also have the option to enter
394 data on salient daily events as they occur, at any time of the day or night. Two questions on
395 subjective sleep quality (duration, disturbance) are administered each morning.

396 Participants are also asked to wear a FitBit Charge 5 wearable continuously to collect
397 data on potential physiological triggers for FND symptoms, including:

- 398 • Sleep quality and duration – measured daily
- 399 • Activity – measured continuously
- 400 • Heartrate – measured continuously

401

402 After the initial two-week period, participants with FND and clinical controls are invited to
403 participate in a further two weeks using the RealLife app to log salient daily events, whilst
404 continuing to wear the Fitbit device.

405 All participants are compensated for completion of the remote monitoring phase with a
406 digital £50 shopping voucher and are able to keep the Fitbit device for their personal use if they
407 have demonstrated adequate engagement with the study (~80% EMA response rate).

408

409 *Follow-up Procedures*

410 Participants with FND and clinical controls are invited to complete 3-, 6- and 12-month follow-
411 ups, which involve completing an abbreviated version of the original online questionnaire pack
412 (Figure 1) and a brief call with a member of the research team. They are also invited to provide

413 their Fitbit data for that follow-up period in pseudonymised format, which can be downloaded
414 on request from the Fitbit consumer-facing platform. The research team are available to support
415 the participant with all remote activities as needed.

416 Participants are compensated for each follow-up with a digital £10 shopping voucher.

417 *End of Study Procedures*

418 The end of the study is defined as the time at which the last participant completes the final
419 research activity (remote follow-up). Following this, we will inform any regulatory bodies (i.e.,
420 the Research Ethics Committee) and the recruitment partners (FND charities and NHS Trusts).
421 After completion of data analysis, the results will be disseminated at academic conferences and
422 in peer-reviewed publications. We will share our findings with the FND-PCAP and other
423 relevant stakeholders via social media, email lists, and/or press releases.

424

425 *Statistical considerations*

426 *Sample size*

427 The overall target sample size was determined on the basis of a power calculation completed
428 in G*Power (Faul et al., 2007). We estimated that for a mixed model ANOVA/ANCOVA,
429 which will be used to test within- and between-groups variation on the primary endpoint of
430 autonomic arousal, a total sample of 180 (n=45 in each 4 groups) would have 80% power to
431 detect a small effect ($f=0.1$) with an alpha of 0.05. Therefore, a total sample of 200
432 participants entering the study will allow for up to five non-completing participants or
433 missing data in each group.

434 On the basis of our pilot study data, we anticipate that approximately 90% of FND
435 patients screened will be eligible and approximately 70% will proceed to complete the study;
436 therefore, we plan to screen ~71 potential participants in each FND group (FS, FMS), to

437 achieve the target sample size (FS n=50; FMS n=50). We predict that approximately 15
438 participants in each group will be ineligible, unsuitable, or unwilling to participate in the
439 neuroimaging session; therefore, the anticipated sample size for this element of the project is
440 n=35 in each of the four study groups (total n=140). For the remote monitoring data analysis,
441 it is estimated that 45 participants per group will allow sufficient statistical power with four
442 variables (affect, dissociation, HR, SCL) entered into a predictive model with momentary
443 FND symptom ratings as the primary outcome variable (Peduzzi et al., 1996).

444

445 *Data processing and statistical analyses*

446 Detailed statistical analysis plans are under development for all elements of the project and
447 these will be finalised and pre-registered before data analysis commences. The nature of all
448 data types are outlined in Table S2.

449 The data will be checked for relevant assumptions (normality of distribution,
450 sphericity, homogeneity of variances) prior to analysis. Non-normally distributed data will be
451 transformed, or non-parametric or robust tests used. The amount and nature of missing data
452 and outliers will be examined for all outcome variables. The approach taken with missing
453 data will depend upon the number of missing values and whether the data is judged to be
454 missing at random or missing not at random. The options for addressing missing data will
455 include variable or participant exclusion, pairwise deletion, single or multiple imputation.
456 Imputation methods will be used where missing data on a given measure does not exceed
457 20%. Outlying data points will be scrutinised and, where appropriate, the values will be
458 Winsorized (replaced with less extreme values). The analyses will be repeated with the
459 original and Winsorized values. Rates of missing data and outliers will be recorded and
460 reported, along with any sensitivity analyses conducted.

461 Recruitment and retention rates will be assessed with descriptive statistics.
462 Demographics and background variables will be analysed with appropriate between-group
463 tests including t-tests, Mann-Whitney tests, and/or Analysis of Variance (ANOVA).
464 Cognitive and experimental task data and autonomic measures will be analysed with
465 between- or mixed between- and within-group tests, such as ANOVA/ANCOVA with
466 covariates added where relevant, and/or multivariate regression analyses. Chi-squared tests
467 will be used for categorical data.

468 Standardised data pre-processing and analysis methods will be adopted for analysis of
469 neuroimaging data. Pre-processing will include reorientation, motion correction, spatial
470 smoothing and normalisation. The neuroimaging data will be analysed with region-of-interest
471 and network connectivity analyses. The primary regions of interest (ROIs) will be: amygdala,
472 periaqueductal grey, and insula. Connectivity analyses will examine functional connectivity
473 patterns between hubs in neural networks involved in affective activation and awareness
474 (amygdala, periaqueductal grey, insula, anterior cingulate cortex) and those involved in motor
475 and cognitive control (motor/premotor areas, dorsolateral prefrontal cortex).

476 The remote monitoring data will be analysed with multilevel modelling, to identify
477 variables (e.g., dissociation, affect, autonomic arousal, life events) that are predictive of FND
478 symptom occurrence/worsening in participants' daily lives. Multilevel models are extensions
479 of the traditional regression model, which account for the nested, hierarchical nature of
480 intensive longitudinal data, by including random effects into model coefficients to account
481 for within-participant variation over time. Furthermore, these techniques are suitable for use
482 when there are missing data and unbalanced numbers of observations, as is often the case in
483 remote measurement studies.

484 The alpha value to be adopted for most statistical tests will be $p \leq 0.05$; however, if
485 multiple tests are conducted with related data (e.g., sub-scales of a questionnaire, post-hoc
486 tests following ANOVA, exploratory tests of multiple neural regions [excluding ROIs]), we
487 will use methods for controlling inflation of familywise error or false discovery rate, such as
488 Bonferroni or Benjamini-Hochberg corrections respectively.

489

490 **Ethical considerations & regulatory approvals**

491 The study is sponsored by King's College London and approved by the North West – Greater
492 Manchester South Research Ethics Committee (ref NW/23/0217). The research will be
493 conducted in compliance with the principles of the Declaration of Helsinki (1996), and in
494 accordance with all applicable regulatory requirements including but not limited to the UK
495 policy framework for health and social care research, Trust and Research Office policies and
496 procedures and any subsequent amendments. All participants will provide written informed
497 consent prior to participation in the study, as described above (Methods section).

498 This protocol has been developed in consultation with the FND-PCAP and a team of
499 academic and clinical collaborators with expertise in FND research and treatment, or relevant
500 methodologies. The conduct, progress and results of the study will be reported to these
501 groups, as well to relevant stakeholders (FND Hope UK, FND Action) and to the approving
502 Research Ethics Committee and institutional research governance office (KCL).

503

504 **Risk management, adverse events & withdrawal**

505 *Risk management & safeguarding*

506 Some of the research activities could potentially be sensitive or challenging for some
507 participants, such as answering questions regarding physical and mental health, difficult

508 cognitive tests, exposure to emotionally significant stimuli, discomfort during the
509 neuroimaging session, and multiple daily prompts during the initial remote monitoring phase.
510 Our pilot study showed that most participants found these elements of the study
511 acceptable/tolerable, although we have incorporated feedback to improve participants’
512 experiences.

513 The research team will ensure that participants are informed clearly about the nature
514 of all tasks, before each activity commences. All participants will be warned that some of the
515 activities might be challenging and that they may experience some degree of discomfort or
516 stress during specific elements of the research. Participants will be reminded that they are
517 free to decline to complete any aspect of the study, or that they may choose to decline
518 specific measures or items, or withdraw from the study at any time, without explanation. The
519 research team will be vigilant for signs of distress throughout the procedures and will pause
520 or end procedures if deemed necessary to ensure the participant’s well-being. During remote
521 monitoring, the research team will be available by telephone and email to answer questions,
522 trouble-shoot and provide any reassurance that participants may require. The Chief
523 Investigator (SP) will arrange to speak to a participant to discuss any distress experienced
524 during the study, on request. A list of support organisations is included in the Participant
525 Information Sheet as standard. Protocols are in place for safeguarding actions to be taken if a
526 participant were to disclose a risk of harm to themselves or another, or if a severe and urgent
527 mental health risk or existing harm became apparent during the course of the study. Adverse
528 events occurring during the study will be monitored and recorded by members of the research
529 team, followed-up by SP, and reported to the KCL Research Governance team and the
530 Research Ethics Committee following established procedures.

531

532 ***Withdrawal/ drop out***

533 Premature withdrawal of participants may occur for the following reasons:

- 534 • participant no longer wishes / is able to take part;
- 535 • change in eligibility status is identified;
- 536 • a protocol violation.

537 If a participant withdraws, or is withdrawn from the study, the data collected from them
538 up to that point will be retained in an anonymised format, and the reason for withdrawal will
539 be recorded if voluntarily provided by the participant. No further data would be collected
540 from participants who withdraw or who are withdrawn.

541 **Data management**

542 All data are stored electronically in secure encrypted databases (e.g., MS Excel), on KCL
543 SharePoint and OneDrive servers. Only immediate members of the research team have access
544 to the databases, as needed. All research data are marked only with a Participant
545 Identification Number (PIN), not with any identifiable data. The linkage data, in which the
546 PIN and identifiable information are associated, is held on a password-protected database,
547 securely on KCL servers. Participant identifiable data will not be shared with any third
548 parties, nor will it be shared outside of European Union countries. Participants have the right
549 to withdraw their identifiable data from the study.

550 The data that participants share with the research team via the GDPR-compliant
551 Qualtrics, LifeData and Fitbit platforms does not contain any identifiable data and is
552 extracted from the platforms by the research team as soon as possible and stored on secure
553 KCL servers. Participants' data will be deleted from the third-party platforms as soon as
554 possible following data extraction. The data are anonymous to the third parties, who have no

555 access to any linkage data, although the data are pseudonymous to the research team who will
556 have access to linkage data.

557 In publications and other reports of the study findings, only aggregated group level
558 data will be presented, in which no single individual would be identifiable. When the study is
559 complete, the data will be held securely for ten years, as specified by the King’s College
560 London data retention policy.

561

562 **Financing and Insurance**

563 This study is funded by a Medical Research Council Career Development Award to SP
564 [2022-2026, ref MR/V032771/1] and is part-funded by the National Institute for Health and
565 Care Research (NIHR) Maudsley Biomedical Research Centre. The sponsor (KCL) will, at
566 all times, maintain adequate insurance in relation to the study through its professional
567 indemnity (Clinical Trials) & no-fault compensation in respect of any claims arising as a
568 result of negligence by its employees, brought by or on behalf of a study participant.

569

570 **Publication and Dissemination**

571 The anonymised, raw data set will be made available on reasonable request and with
572 consultation with the KCL Data Management team. The research findings will be presented
573 at academic conferences and published in peer-reviewed journal articles, as well as being
574 disseminated to a wider audience through social media channels and/or other public relations
575 and media outlets.

576 Participants will be informed that the results will be published and will be offered the
577 opportunity to receive a summary of the publications and electronic links to the outputs on
578 request.

579

580 **Discussion**

581 Evidence for several hypothesised pathophysiological mechanisms in FND is limited at present
582 due to methodological constraints in previous studies (Drane et al., 2020; Pick et a., 2019).
583 This project employs a novel combination of multimodal research methods to rigorously
584 examine several putative mechanisms in FND, at multiple levels of explanation, using
585 subjective/experiential, behavioural, and physiological measures. The study is testing causal
586 hypotheses about the role of altered emotional processing, autonomic arousal, dissociation and
587 interoception in the initiation or exacerbation of FND symptoms, directly comparing these
588 processes in FS and FMS. We aim to control, or account for, a range of common confounding
589 factors, including comorbid psychiatric symptoms, medication use, and general cognitive
590 functioning.

591 This is the first study to directly compare FND subgroups using such diverse and
592 comprehensive methods in a relatively large sample, including both clinical and healthy
593 comparison groups. By examining these mechanistic processes in both laboratory and
594 naturalistic contexts, we will ascertain the consistent influences and underlying processes that
595 might explain the occurrence of FND symptoms across settings. The combination of
596 neuroimaging, psychophysiology, and momentary subjective probes will allow us to examine
597 the simultaneous neural, autonomic, and psychological processes that precede subtle variations
598 in subjective FND symptoms from moment-to-moment. The use of remote monitoring
599 technologies will highlight the physiological, psychological and environmental factors
600 influencing FND symptoms in real-time and real-world settings. Moreover, the inclusion of
601 longitudinal follow-ups will establish whether specific aetiological factors and mechanistic
602 features are predictive of longer-term clinical outcomes in FS and FMS.

603 The results of this study have the potential to lead to significant progression in
604 aetiological and mechanistic models of FND, and will likely uncover meaningful, evidence-
605 based targets for prevention and intervention of FND in future.

606

607

608 **Funding:** The study is funded by a Medical Research Council Career Development Award to SP
609 [MR/V032771/1]. This project also represents independent research part-funded by the National
610 Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London and
611 Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of
612 the authors and not necessarily those of the NHS, the NIHR or the Department of Health and
613 Social Care.

614
615 **Conflicts of interest:** None.

616
617 **Author contributions:** Funding acquisition: SP (lead), MH, TC, MAM (supporting).
618 Conceptualisation: SP. Design/methodology: SP (lead), MH, TC, MAM, ASD, LSMM, AATSR,
619 MJE, LHG, TRN, JSW (supporting). Project administration: SP. Resources: SP (lead), MH, TC
620 (supporting). Writing: SP (original draft/review and editing), MAM, TC, MH, LSMM, LHG, MJE,
621 TRN, JSW, ASD, BS (review and editing). All authors reviewed and approved the final version of
622 the manuscript.

623

624 **References**

- 625
626 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
627 disorders (5th ed.).
628
- 629 Aybek, S., Nicholson, T. R., O’Daly, O., Zelaya, F., Kanaan, R. A., & David, A. S. (2015).
630 Emotion-motion interactions in conversion disorder: an fMRI study. *PloS one*, 10(4),
631 e0123273.
632
- 633 Bagby, R. M., Parker, J. A. D, Taylor, G. J. (1994). The twenty-item Toronto Alexithymia
634 scale—I. Item selection and cross-validation of the factor structure. *Journal of Psychosomatic
635 Research*, 38(1), 23-32, [https://doi.org/10.1016/0022-3999\(94\)90005-1](https://doi.org/10.1016/0022-3999(94)90005-1).
636
- 637 Bakvis, P., Roelofs, K., Kuyk, J., Edelbroek, P. M., Swinkels, W. A., & Spinhoven, P.
638 (2009). Trauma, stress, and preconscious threat processing in patients with psychogenic
639 nonepileptic seizures. *Epilepsia*, 50(5), 1001-1011.
640
- 641 Baron-Cohen, S. Wheelwright, R. Skinner, J. Martin and E. Clubley, (2001). The Autism
642 Spectrum Quotient (AQ) : Evidence from Asperger Syndrome/High Functioning Autism,
643 Males and Females, Scientists and Mathematicians. *Journal of Autism and Developmental
644 Disorders*, 31:5-17.
645
- 646 Briere, J., Weathers, F. W., Runtz, M. (2005). Is dissociation a multidimensional construct?
647 Data from the Multiscale Dissociation Inventory. *J Trauma Stress*, 18(3):221-31. doi:
648 10.1002/jts.20024.
649
- 650 Broadbent, D.E., Cooper, P.F., FitzGerald, P. and Parkes, K.R. (1982), The Cognitive
651 Failures Questionnaire (CFQ) and its correlates. *British Journal of Clinical Psychology*, 21:
652 1-16. <https://doi.org/10.1111/j.2044-8260.1982.tb01421.x>
653
- 654 Broadbent, E., Petrie, K. J., Main, J., Weinman, J. (2006). The Brief Illness Perception
655 Questionnaire. *Journal of Psychosomatic Research*, 60(6):631-637,
656 <https://doi.org/10.1016/j.jpsychores.2005.10.020>.
657
- 658 Brown, R. J., & Reuber, M. (2016). Psychological and psychiatric aspects of psychogenic
659 non-epileptic seizures (PNES): a systematic review. *Clinical Psychology Review*, 45, 157-
660 182.
661
- 662 Campbell, M., Smakowski, A., Rojas-Aguiluz, M., Goldstein, L., Cardeña, E., Nicholson, T.,
663 . . . Pick, S. (2023). Dissociation and its biological and clinical associations in functional
664 neurological disorder: Systematic review and meta-analysis. *BJPsych Open*, 9(1), E2.
665 doi:10.1192/bjo.2022.597
666
- 667 Carson, A., & Lehn, A. (2016). Epidemiology. *Handbook of Clinical Neurology*, 139, 47-60.
668
- 669 Drane, D., Fani, N., Hallett, M., Khalsa, S., Perez, D., & Roberts, N. (2021). A framework for
670 understanding the pathophysiology of functional neurological disorder. *CNS Spectrums*,
671 26(6), 555-561. doi:10.1017/S1092852920001789

- 672
673 Espay, A. J., Maloney, T., Vannest, J., Norris, M. M., Eliassen, J. C., Neefus, E., ... &
674 Szaflarski, J. P. (2018). Impaired emotion processing in functional (psychogenic) tremor: a
675 functional magnetic resonance imaging study. *NeuroImage: Clinical*, 17, 179-187.
676
677 Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical
678 power analysis program for the social, behavioral, and biomedical sciences. *Behavior*
679 *Research Methods*, 39(2), 175–191. <https://doi.org/10.3758/BF03193146>
680
681 First, M.B. & Williams, J.B.W. (2021). Quick Structured Clinical Interview for DSM-5®
682 Disorders (QuickSCID-5). American Psychiatric Association Publishing.
683
684 Gabriele, E., Spooner, R., Brewer, R., & Murphy, J. (2022). Dissociations between self-
685 reported interoceptive accuracy and attention: Evidence from the Interoceptive Attention
686 Scale. *Biological Psychology*, 168, 108243.
687
688 Guy, W. B. R. R. (1976). CGI. Clinical global impressions. ECDEU assessment manual for
689 psychopharmacology.
690
691 Hays, R. D., Sherbourne, C. D., Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0.
692 *Health Econ*, 2(3):217-27. doi: 10.1002/hec.4730020305. PMID: 8275167.
693
694 Koreki, A., Garfinkel, S. N., Mula, M., Agrawal, N., Cope, S., Eilon, T., ... & Yogarajah, M.
695 (2020). Trait and state interoceptive abnormalities are associated with dissociation and
696 seizure frequency in patients with functional seizures. *Epilepsia*, 61(6), 1156-1165.
697
698 Kroenke, K., Spitzer, R. L., Williams, J. B. (2001). The PHQ-9: validity of a brief depression
699 severity measure. *J Gen Intern Med*, 16(9):606-13. doi: 10.1046/j.1525-
700 1497.2001.016009606.x.
701
702 Kroenke, K., Spitzer, R. L., Williams, J. B. (2002). The PHQ-15: validity of a new measure
703 for evaluating the severity of somatic symptoms. *Psychosom Med*, 64(2):258-66. doi:
704 10.1097/00006842-200203000-00008.
705
706 Mehling, W. E., Acree, M., Stewart, A., Silas, J., Jones, A. (2018). The Multidimensional
707 Assessment of Interoceptive Awareness, Version 2 (MAIA-2). *PLoS One*, 13(12). doi:
708 10.1371/journal.pone.0208034.
709
710 Morsy, S. K., Aybek, S., Carson, A., Nicholson, T. R., Stone, J., Kamal, A. M., ... & Kanaan,
711 R. A. (2021). The relationship between types of life events and the onset of functional
712 neurological (conversion) disorder in adults: a systematic review and meta-analysis.
713 *Psychological Medicine*, 1-18.
714
715 Mundt, J. C., Marks, I.M., Shear, M.K., Greist, J.H. (2002). The Work and Social Adjustment
716 Scale: a simple measure of impairment in functioning. *Br J Psychiatry*, 180:461-4. doi:
717 10.1192/bjp.180.5.461.
718

- 719 Nijenhuis, E. R., Spinhoven, P., Van Dyck, R., Van der Hart, O., Vanderlinden, J. (1996).
720 The development and psychometric characteristics of the Somatoform Dissociation
721 Questionnaire (SDQ-20). *J Nerv Ment Dis*, 184(11):688-94. doi: 10.1097/00005053-
722 199611000-00006.
- 723
724 Nijenhuis, E.R.S., Van der Hart, O. and Kruger, K. (2002), The psychometric characteristics
725 of the traumatic experiences checklist (TEC): first findings among psychiatric outpatients.
726 *Clin. Psychol. Psychother*, 9: 200-210. <https://doi.org/10.1002/cpp.332>
- 727
728 Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996). A simulation
729 study of the number of events per variable in logistic regression analysis. *Journal of clinical*
730 *epidemiology*, 49(12), 1373–1379. [https://doi.org/10.1016/s0895-4356\(96\)00236-3](https://doi.org/10.1016/s0895-4356(96)00236-3)
- 731
732 Pick, S., Anderson, D. G., Asadi-Pooya, A. A., Aybek, S., Baslet, G., Bloem, B. R., ... &
733 Nicholson, T. R. (2020). Outcome measurement in functional neurological disorder: a
734 systematic review and recommendations. *Journal of Neurology, Neurosurgery & Psychiatry*,
735 91(6), 638-649.
- 736
737 Pick, S., Goldstein, L. H., Perez, D. L., & Nicholson, T. R. (2019). Emotional processing in
738 functional neurological disorder: a review, biopsychosocial model and research agenda.
739 *Journal of Neurology, Neurosurgery & Psychiatry*, 90(6), 704-711.
- 740
741 Pick, S., Mellers, J. D., & Goldstein, L. H. (2016). Explicit facial emotion processing in
742 patients with dissociative seizures. *Psychosomatic medicine*, 78(7), 874-885.
- 743
744 Pick, S., Mellers, J. D., & Goldstein, L. H. (2018a). Autonomic and subjective responsivity to
745 emotional images in people with dissociative seizures. *Journal of neuropsychology*, 12(2),
746 341-355.
- 747
748 Pick, S., Mellers, J. D., & Goldstein, L. H. (2018b). Implicit attentional bias for facial
749 emotion in dissociative seizures: additional evidence. *Epilepsy & Behavior*, 80, 296-302.
- 750
751 Pick, S., Rojas-Aguiluz, M., Butler, M., Mulrenan, H., Nicholson, T. R., & Goldstein, L. H.
752 (2020). Dissociation and interoception in functional neurological disorder. *Cognitive*
753 *Neuropsychiatry*, 25(4), 294-311.
- 754
755 Plans, D., Ponzo, S., Morelli, D., Cairo, M., Ring, C., Keating, C. T., ... & Bird, G. (2021).
756 Measuring interoception: The phase adjustment task. *Biological psychology*, 165, 108171.
- 757
758 Reuber, M. (2009). The etiology of psychogenic non-epileptic seizures: toward a
759 biopsychosocial model. *Neurologic Clinics*, 27(4), 909-924.
- 760
761 Roberts, N. A., Burleson, M. H., Weber, D. J., Larson, A., Sergeant, K., Devine, M. J., ... &
762 Wang, N. C. (2012). Emotion in psychogenic nonepileptic seizures: responses to affective
763 pictures. *Epilepsy & Behavior*, 24(1), 107-115.
- 764
765 Ryan, E. G., Vitoratou, S., Goldsmith, K. A., & Chalder, T. (2018). Psychometric Properties
766 and Factor Structure of a Long and Shortened Version of the Cognitive and Behavioural

- 767 Responses Questionnaire. *Psychosomatic medicine*, 80(2), 230–237.
768 <https://doi.org/10.1097/PSY.0000000000000536>
769
770 Spitzer, R. L., Kroenke, K., Williams, J. B., Löwe, B. (2006). A brief measure for assessing
771 generalized anxiety disorder: the GAD-7. *Arch Intern Med*, 166(10):1092-7. doi:
772 10.1001/archinte.166.10.1092.
773
774 Stone, J., Carson, A., Duncan, R., Roberts, R., Warlow, C., Hibberd, C., ... & Sharpe, M.
775 (2010). Who is referred to neurology clinics? The diagnoses made in 3781 new patients.
776 *Clinical Neurology and Neurosurgery*, 112(9), 747-751.
777
778 World Health Organization. (2019). *International statistical classification of diseases and*
779 *related health problems (11th ed.)*.

Figure 1. Flowchart of study procedures

	Screening interview (remote)	Questionnaire pack (online)	Laboratory visit (KCL)	Neuroimaging visit (KCL)	Initial remote monitoring (2-4 weeks)	FU-1 (3m)	FU-2 (6m)	FU-3 (12m)
Informed consent	X			X	X			
Demographics	X							
Medical history	X							
FNS Questionnaire		X				X	X	X
CGI-Severity	X							
CGI-Improvement		X			X	X	X	X
Quick SCID	X							
MAIA-2		X				X	X	X
IAccS		X				X	X	X
IAttS		X				X	X	X
TAS-20		X				X	X	X
MDI		X				X	X	X
SDQ-20		X				X	X	X
PHQ-9		X				X	X	X
PHQ-15		X				X	X	X
PDS-5		X				X	X	X
TEC		X						
GAD-7		X				X	X	X
SF-36		X				X	X	X
WSAS		X				X	X	X
BIPQ		X				X	X	X
CBRQ		X				X	X	X
CFQ		X				X	X	X
AQ		X						
WASI-II			X					
CANTAB battery			X					
Performance validity test			X					
Hand grip task			X					
Heartbeat monitoring task(s)			X	X				
Psychophysiology (ECG, EDA)			X					
Mock MRI scan			X					
MRI task training			X	X				
Structural MRI scans				X				
Resting state MRI scan				X				
Task-based MRI scans				X				
EMA					X			
Fitbit monitoring					X	X	X	X

Key: AQ=Autism Spectrum Quotient; BIPQ=Brief Illness Perceptions Questionnaire; CANTAB=Cambridge Neuropsychological Test Automated Battery; CBRQ=Cognitive Behavioural Responses to Symptoms Questionnaire; CFQ=Cognitive Failures Questionnaire; CGI=Clinical Global Impression; ECG=electrocardiography; EMA= ecological momentary assessment; EDA=electrodermal activity; EEG=electroencephalography; FNS=Functional Neurological Symptoms; GAD-7=Generalized Anxiety Disorder-7; IAccS; Interoceptive Accuracy Scale; ; IAttS; Interoceptive Attention Scale; KCL=King's College London; MAIA-2=Multidimensional Assessment of Interoceptive Awareness-2nd edition; MDI=Multiscale Dissociation Inventory; MRI=magnetic resonance imaging; PDS=Post-Traumatic Diagnostic Scale; PHQ=Patient Health Questionnaire; SCID=Structured Clinical Interview for DSM-5; SDQ-20=Somatoform Dissociation Questionnaire-20; SF-36=Short Form Health Survey-36; TAS-20=Toronto Alexithymia Scale-20; TEC=Traumatic Experiences Checklist; WASI-II=Wechsler Abbreviated Scale of Intelligence-2nd edition; WSAS=Work and Social Adjustment Scale